secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001193125-24-151049
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm shareholders approve 6M share increase in equity plan, 5M in ESPP, and option exchange
--------------------------------------------------------------------------------

- Stockholders approved Class II directors: Deepika R. Pakianathan, Richard Paulson, Chen Schor (all three-year terms).
- Amendment to 2022 Equity Plan approved: adds 6,000,000 shares for issuance.
- ESPP Amendment approved: adds 5,000,000 shares for issuance.
- Stockholders approved a one-time stock option exchange program for non-executive officer employees.
- Ratified Ernst & Young as independent auditor for FY2024 (87.7M for, 2.5M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524151049/0001193125-24-151049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524151049/d827879d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-151049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer